JE
Therapeutic Areas
Orega Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IPH5201 (anti-CD39 mAb) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 |
| Undisclosed Antibody Program | Undisclosed | Pre-clinical |
| Drug | Indication | Phase |
|---|---|---|
| IPH5201 (anti-CD39 mAb) | Non-Small Cell Lung Cancer (NSCLC) | Phase 2 |
| Undisclosed Antibody Program | Undisclosed | Pre-clinical |